Peptides Studied for Supporting Immune Defence and Regulation
Researchers have studied several peptides for their effects on immune function — some that stimulate immune cells, some that kill microbes directly, and some that calm an overactive response. The strongest human evidence supports thymus-derived peptides like thymosin alpha-1 and thymalin, and the synthetic dipeptide pidotimod, mostly in people with infections or weakened immunity. Others, like elafin, alpha-MSH and KPV, rest mainly on laboratory and animal work.
1The biology of this goal
Your immune system has several layers. The first-line defences respond quickly to any threat — cells that swallow microbes, and small proteins the body makes that kill bacteria and fungi directly. Behind them sits a slower, more targeted system built around T-cells, which learn to recognise specific threats. A healthy response also needs an off-switch: inflammation that goes on too long or too strong damages your own tissue. The peptides here act at different points. Some train and activate immune cells. Some are natural antimicrobial proteins found in milk, tears, skin and lung. Some do both, and some mainly work to keep the response from overshooting.
Human trials and preclinical studies report improvements in immune cell subsets and its use as an immune enhancer in viral infections such as hepatitis B, hepatitis C and AIDS.
Thymosin alpha-1 is a 28-amino-acid peptide the thymus gland naturally makes. It helps train and coordinate immune cells — encouraging T-cells to mature, and activating natural killer cells and dendritic cells that detect and destroy threats. It is described as able to both boost a weak immune response and support defence against viruses, bacteria and tumours.
Thymosin alpha-1 was originally isolated from thymic tissue as the compound that restored immune function to mice with their thymus removed.1
It acts through Toll-like receptors on dendritic cells to trigger signalling and production of immune-related cytokines, and would be expected to help treat immune suppression related to aging, infection or cancer.1
An expert consensus review of thymosin alpha-1 states that the peptide may enhance innate immunity and increase the activity of NK cells and macrophages, effects the authors describe as helping prevent invasion by external pathogens including bacteria and viruses.2
It binds TLR3/4/9 and activates IRF3 and NF-κB pathways, promoting proliferation and activation of immune cells and enhancing both innate and adaptive responses.3
What this doesn't establish
The evidence centres on people with existing infection, cancer or immune suppression; it does not establish that it strengthens immunity in healthy individuals.
Animal and laboratory studies suggest antimicrobial and antiviral activity, with one tier-1 review describing its antimicrobial and immune-modulating functions.
Elafin is a human protein made naturally in the skin, lung and breast. It protects tissue by blocking destructive enzymes released by immune cells during inflammation, and it also kills microbes directly. This makes it part of the body's first-line defence at surfaces exposed to the outside world.
Elafin and its precursor trappin-2 have been associated with mucosal resistance to HIV-1 infection, and pretreating genital epithelial cells with them significantly reduced HSV-2 virus titres.4
Elafin has defensin-like antimicrobial activity in vitro against bacteria and fungi, and was active against Pseudomonas aeruginosa infection in mice using a gene-transfer strategy.5
Elafin has antimicrobial function and modulates innate and adaptive immunity.6
What this doesn't establish
Much of the antiviral data comes from cell cultures and gene-transfer models in mice; no human trial shows that supplementing elafin strengthens immunity or prevents infection.
Human trials report a favourable safety profile and a meta-analysis in which most included studies showed improvements in at least one biomarker of immune function.
Lactoferrin is a natural defence protein found in milk, tears, saliva and the immune cells called neutrophils. It kills a broad range of microbes, partly by locking away the iron that many bacteria need to grow. It also helps calm inflammation and regulate the immune system.
Human lactoferrin is a natural defence protein present in body fluids, secretions and neutrophils with broad-spectrum antimicrobial activity, and its levels fall after stem-cell transplant, contributing to immune deficiency.7,8
The peptide fragment hLF1-11 was tolerable up to 5 mg intravenously in healthy volunteers, with a very favourable side-effect profile for an antimicrobial.7,8
In a systematic review and meta-analysis, eight of 13 studies reported improvements in at least one biomarker of immune function following lactoferrin supplementation.9
What this doesn't establish
Improvement in a biomarker is not the same as fewer or milder infections; the clinical benefit of supplementation for immune resilience is not established.
Human clinical studies over three decades report reduced rates of recurrent respiratory and urinary infections and beneficial effects on cytokines and humoral immunity.
Pidotimod is a synthetic dipeptide — two amino acids joined together — that acts as an immune modulator. It works on both the fast innate defences and the slower targeted adaptive defences, helping the body respond to infection. It has mainly been studied for preventing recurrent respiratory and urinary infections.
Pidotimod is a synthetic dipeptide with activity on both adaptive and innate immunity, confirmed in vitro and in vivo, with effects more evident in immune defects such as senescence, Down syndrome and cancer.10
Its multifaceted mechanism modulates innate and adaptive immunity, with beneficial effects on cytokines and humoral immunity in HIV patients, and preliminary evidence of shortening COVID-19 duration and severity.11
It exerts its effects by stimulating dendritic cells, enhancing TLR expression and promoting IL-2 and IFN-γ production, supporting both cellular and humoral immunity.12
What this doesn't establish
Its documented benefit is in preventing recurrent infection in susceptible or immunocompromised groups; it does not establish enhanced immunity in already-healthy people.
Human studies report that it normalises cellular and humoral immunity and restores immune cell counts, often as part of combination therapy in chronic infection or immune dysfunction.
Imunofan is a small synthetic peptide modelled on a fragment of thymopoietin, a natural thymus hormone that guides immune T-cells. Rather than simply revving the immune system up, it is described as nudging abnormal immune measures back toward balance. It has been used alongside standard treatment for chronic infections and immune problems.
Imunofan is able to restore cell immunity, the oxygen-dependent neutrophilic bactericidal system and antiviral antibody production, and enhances antiviral and antibacterial immunity in chronic infections such as brucellosis and hepatitis B and C.13
In type 2 diabetes patients with diabetic foot syndrome, imunofan significantly normalised cellular and humoral immunity.14
Combined with myelopid in patients with chronic suppurative otitis media, it was more effective than conventional antibacterial therapy alone at restoring T-helper, B-lymphocyte and phagocyte counts.15
What this doesn't establish
The trials are small, mostly Russian-language, and often combine it with other agents; its independent effect on immune resilience in healthy people is not established.
Evidence is mixed in strength: a tier-1 review confirms thymic peptides' immunomodulatory role in clinical use, while a tier-2 study links thymulin depletion to malnutrition, and mechanistic claims about thymulin itself rest partly on tier-3 vendor sources.
Thymulin is a small nine-amino-acid hormone made by the thymus gland, and it only works when bound to zinc. It helps immature T-cells develop, tunes the balance of immune cell types, and calms excessive inflammation. Because it needs zinc, its levels drop when zinc or nutrition is lacking.
In 58 Senegalese children who died at various stages of malnutrition, thymic atrophy and depleted thymulin content were associated with severe protein-energy malnutrition but not with depleted thymic zinc content, which remained high regardless of nutritional state.16
Thymic peptides, including thymulin, act on the immune system by stimulating T-cell differentiation and maturation, regulating NK and dendritic cells, and are used for viral infections, autoimmune diseases and immunodeficiencies.17
Thymulin is described as regulating the immune system and T-cell differentiation, with preclinical research suggesting anti-inflammatory and immune-modulating properties.18
What this doesn't establish
There is no direct human trial showing that giving thymulin strengthens immunity; the human data describe it as a marker of thymic and zinc status rather than a proven intervention.
Human clinical reports, largely from the Khavinson group, describe restored immune function, reduced respiratory infection incidence, and improved immune status in severe COVID-19 and various infectious diseases.
Thymalin is a mixture of small peptides extracted from the thymus gland of young calves, used as an immune regulator. It is said to help bone-marrow precursor cells mature into T-lymphocytes and to restore balance to the immune system. Because it is a mixture rather than one defined molecule, its effects are described as broad but less targeted.
Thymalin is a polypeptide drug used for immune dysfunction, viral and bacterial infections, and immunodepression; it normalises immune function, stimulates regeneration and hematopoiesis, and reduced mortality in elderly patients.19
Its short peptides regulate synthesis of immune system proteins and gerontogene activity, and it has been reported effective in infectious diseases including hepatitis A and B, erysipelas, meningococcal infection and typhoid fever.21
As an immune modulator, thymalin combined with norcolut and myelopid increased treatment effectiveness for hyperplastic endometrial processes in 55 patients.20
What this doesn't establish
The clinical evidence comes largely from a single research group and includes case-report-level data; independent, blinded trials confirming immune benefit are lacking.
Animal and laboratory studies suggest direct antimicrobial and anti-inflammatory activity, while a tier-1 tumour study shows its melanocortin signalling can also suppress antitumour immunity.
Alpha-MSH is a small natural hormone, best known for driving skin tanning and calming inflammation. Researchers have also noticed it shares features with the body's natural germ-killing peptides, and reports describe it directly killing certain bacteria and fungi. This dual role — calming inflammation while fighting microbes — is why it is studied in the context of immune defence.
α-MSH shares characteristics with antimicrobial peptides and has direct antimicrobial activity against fungal and bacterial pathogens, with its C-terminal residues showing antimicrobial activity parallel to the whole peptide.22
In cancer models, α-MSH acting through MC5R promoted myelopoiesis and immunosuppression to accelerate tumour growth, and an MC5R antagonist boosted antitumour immunity and anti-PD-1 immunotherapy.23
α-MSH downstream signalling may promote immune escape and cancer resistance to therapy.24
What this doesn't establish
The antimicrobial data are laboratory-based, and the same signalling can be immunosuppressive in cancer; there is no human evidence that α-MSH strengthens immune resilience.
Animal and laboratory studies suggest anti-inflammatory and antimicrobial activity, including in cell cultures and mouse colitis models.
KPV is a three-amino-acid fragment (Lys-Pro-Val) taken from the tail end of alpha-MSH. Most sources describe it as calming inflammation, but it also has reported germ-killing activity against certain bacteria and fungi. It is studied as part of the body's non-specific first-line defence, especially at mucosal surfaces like the gut.
KPV, the carboxy-terminal tripeptide of α-MSH, has antimicrobial effects against Staphylococcus aureus and Candida albicans over a broad concentration range including the physiological picomolar range, possibly mediated by increasing cellular cAMP.25
KPV acts via the PepT1 transporter expressed in immune and intestinal epithelial cells, where nanomolar concentrations inhibit NF-κB signalling and reduce inflammation in mouse colitis models.27
Authors of one animal and laboratory study suggested that therapeutic application of KPV, and KPV-pulsed dendritic cells, may be a useful approach for inflammatory, autoimmune and allergic diseases.26
What this doesn't establish
All evidence is preclinical; no human trial establishes that KPV strengthens immunity or resolves infection in people.
These compounds split into overlapping families. The thymus-derived immunomodulators — thymosin alpha-1, thymalin, thymulin and imunofan — largely do the same job: normalising T-cell subsets, boosting NK activity and dampening inflammatory cytokines. Pairing them together is mostly redundant rather than additive, and the sensible approach is to pick one thymic signal rather than layering several. Pidotimod reaches similar adaptive-immunity endpoints through a different upstream route (dendritic-cell maturation and Th1 skewing), so it overlaps with the thymic peptides but can also complement them; stacking multiple immunostimulants adds little and warrants monitoring. The antimicrobial and anti-inflammatory group works differently and complements the T-cell peptides: lactoferrin (iron sequestration) and elafin (protease inhibition) are two arms of innate mucosal immunity through distinct mechanisms and are described as synergistic. KPV is literally the C-terminal tail of alpha-MSH and shares its NF-κB braking action, so combining those two for inflammation is largely redundant — alpha-MSH simply adds melanocortin effects (tanning, appetite) that KPV was designed to avoid. KPV and elafin, by contrast, restrain inflammation at mucosal surfaces by complementary means.
Thymulin + Thymalin
Worth caution — see why below
Both are thymus-derived immune regulators that drive T-lymphocyte precursor maturation, normalize CD4/CD8 balance, boost NK activity, and dampen NF-kB-driven pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha). Thymulin is essentially one of the discrete thymic hormones whose activity Thymalin (a thymic peptide complex) is meant to restore. Running both together is largely redundant rather than additive — pick one thymic immunomodulator and dose it properly rather than layering two overlapping thymic signals.
Thymulin + Pidotimod
Worth caution — see why below
Thymulin is a thymic hormone that drives T-lymphocyte maturation, tunes CD4/CD8 balance and boosts NK cytotoxicity — the same adaptive-immunity endpoints pidotimod promotes through dendritic-cell maturation and Th1 differentiation. They reach the same destination by different upstream mechanisms, which can be complementary for immune-deficiency support but also overlapping; stacking multiple immunostimulants adds little beyond one and should be monitored.
Thymulin + Thymosin Alpha-1
Worth caution — see why below
Thymulin is a thymic hormone that, like Thymosin Alpha-1, drives T-lymphocyte precursor maturation, tunes CD4/CD8 balance, enhances NK cytotoxicity, and suppresses excess inflammatory cytokines. They occupy the same thymic-immune niche, so combining them mostly duplicates the same effect rather than adding a new mechanism.
Thymulin + Imunofan
Worth caution — see why below
Both are thymus-derived peptide hormones that normalize T-cell maturation, CD4/CD8 balance and NK cytotoxicity while dampening pro-inflammatory cytokines. Because they converge on the same thymic immune-tuning output, running them together is largely redundant rather than additive — pick one thymic immunomodulator rather than stacking two.
What the research doesn't establish
Although both peptides influence T-cell maturation, CD4/CD8 balance, NK activity and cytokine levels, they act through different molecular routes: Imunofan signals via thymopoietin receptors and cyclase/PKC pathways, whereas Thymulin depends on zinc-activated peptide, NF-κB/p38 MAPK inhibition and α7-nicotinic receptors. Shared functional endpoints do not establish that the two work through the same mechanism or that combining them is redundant.
Lactoferrin + Alpha-MSH
Worth caution — see why below
Lactoferrin defends against microbes largely by sequestering iron and binding microbial surfaces, and calms inflammation via immune modulation — a completely different route from alpha-MSH's melanocortin/NF-κB-based antimicrobial and anti-inflammatory action. The two converge on innate immune defense through non-overlapping mechanisms, which is the hallmark of a complementary combination.
Thymalin + Pidotimod
Worth caution — see why below
Pidotimod reaches the same immune-support goal by a different route — it matures dendritic cells via TLR-2/TLR-7 and pushes Th1 differentiation and immunoglobulin production, whereas Thymalin works through thymic T-cell maturation. Because they enter the immune network at different points (antigen-presenting-cell activation vs. T-cell precursor maturation), they can plausibly complement each other rather than duplicate.
Thymalin + Thymosin Alpha-1
Worth caution — see why below
Both are thymus-derived immune-restoration peptides that normalize T-lymphocyte subsets, boost NK activity, and dampen pro-inflammatory cytokines. Because they push the same immune levers (thymic T-cell maturation and cytokine balancing), running them together is largely redundant rather than additive — pick one thymic immunomodulator rather than layering them.
Thymalin + Imunofan
Worth caution — see why below
Imunofan is built on a thymopoietin fragment and acts as a bidirectional thymic-type immunomodulator — normalizing CD4/CD8 ratios, enhancing phagocytosis/NK activity, and reducing TNF/IL-6. That overlaps heavily with Thymalin's thymic T-cell restoration, so the two are largely doing the same job through the same thymic-hormone logic. Combining them adds little beyond either alone.
What the research doesn't establish
Although both peptides normalize T-cell balance, modulate cytokines, and enhance phagocytosis, they do not do so through the same molecular route. Thymalin acts via DNA/histone binding and NF-kB-linked gene regulation, whereas Imunofan signals through thymopoietin membrane receptors, cAMP/PKA, and redox pathways—so their overlapping effects are convergent, not evidence of a shared mechanism.
Pidotimod + Thymosin Alpha-1
Worth caution — see why below
Pidotimod, like Thymosin Alpha-1, acts through Toll-like receptors (TLR2/TLR7), promotes dendritic-cell maturation, and pushes Th1 differentiation and NK activity. Because both are upstream innate/adaptive immune activators hitting the same TLR-DC-Th1 pathway, stacking them is redundant and could over-stimulate the same axis.
Pidotimod + Imunofan
Worth caution — see why below
Pidotimod drives dendritic-cell maturation, Th1 differentiation, immunoglobulin production and phagocytosis through TLR2/TLR7 — a different upstream trigger than imunofan's thymopoietin pathway, but both raise T-cell competence and antimicrobial defense. They can complement each other for immune support, though effects on the same output should be monitored to avoid over-stimulation.
Thymosin Alpha-1 + Imunofan
Worth caution — see why below
Imunofan is a thymopoietin-fragment immunocorrector that normalizes T-cell ratios, boosts phagocyte and NK function, and modulates the Th1/Th2 cytokine balance — the same homeostatic immune-restoration role Thymosin Alpha-1 plays. Stacking two thymic-type immunomodulators is redundant; choose one based on the goal.
What the research doesn't establish
Although both peptides influence T-cell function and Th1/Th2 balance, they act through distinct receptor systems and signaling cascades: Thymosin Alpha-1 works via Toll-like receptors (TLR2/3/4/7/9) and MHC Class I through IRF3, NF-κB and MyD88 pathways, whereas Imunofan acts on thymopoietin receptors and P-glycoprotein via adenylate cyclase, guanylate cyclase and PKC. A shared immune-restoring outcome does not mean they share a mechanism or are interchangeable.
Elafin + Alpha-MSH
Worth caution — see why below
Elafin protects tissue by inhibiting neutrophil serine proteases and dampening NF-κB, whereas alpha-MSH suppresses inflammation through melanocortin/cAMP signaling and NF-κB. Both also carry antimicrobial activity. These are different upstream mechanisms landing on the same goal of resolving inflammation and protecting mucosal/tissue surfaces, making them a complementary pairing.
Alpha-MSH + KPV
Worth caution — see why below
KPV is literally the C-terminal three-amino-acid tail (Lys-Pro-Val) of alpha-MSH and carries over the parent hormone's anti-inflammatory action — stabilising IκBα and suppressing NF-κB. In fact KPV was developed as the anti-inflammatory 'business end' of alpha-MSH without the pigmentation and appetite effects. Stacking the two for inflammation is largely redundant because they push the same NF-κB brake; alpha-MSH just adds melanocortin-receptor effects (tanning, appetite) that KPV was designed to avoid. Choose based on whether you want those extra effects, rather than combining for additive anti-inflammatory benefit.
Lactoferrin + Elafin
May be complementary
Lactoferrin defends by sequestering iron away from microbes and calming inflammation, while elafin blocks neutrophil serine proteases. They are two arms of innate mucosal immunity working through different mechanisms toward the same goal of infection control and reduced inflammatory tissue damage.
Elafin + KPV
May be complementary
Both dampen inflammation at mucosal surfaces largely by restraining NF-κB signaling, but by different means: KPV (an α-MSH fragment) suppresses inflammatory cytokines and stabilizes IκBα, while elafin blocks tissue-destroying proteases. In a gut/mucosal setting they address inflammation and barrier protection from complementary angles.
Thymulin + Lactoferrin
No known conflict in the research
Thymulin fine-tunes T-cell maturation and dampens excess pro-inflammatory cytokines, while lactoferrin acts on the innate/antimicrobial front. Their immune roles are distinct but converge on balanced immune function, making them a plausible complementary immune-support pairing.
Thymulin + Elafin
No known conflict in the research
Thymulin normalizes T-cell balance and tamps down excess pro-inflammatory cytokines via NF-κB inhibition, while elafin controls neutrophil protease-driven tissue damage. They modulate adaptive and innate immunity from different angles toward a calmer, better-regulated immune response.
Thymulin + Alpha-MSH
No known conflict in the research
Alpha-MSH suppresses NF-kB (preserving IkBα) and calms inflammatory cytokines through melanocortin receptors, a different upstream mechanism than thymulin's zinc-dependent immune regulation, but both converge on reduced inflammatory cytokine output.
Thymulin + KPV
No known conflict in the research
Thymulin normalises T-cell balance and suppresses excess proinflammatory cytokines via NF-κB and p38 MAPK inhibition, while KPV independently dampens NF-κB-driven cytokine production. Both converge on restraining overactive inflammation through complementary immune mechanisms (adaptive T-cell tuning vs innate cytokine suppression).
Lactoferrin + Thymalin
No known conflict in the research
Lactoferrin supports innate defense through direct antimicrobial/iron-sequestering and cytokine-calming actions, a different mechanism from Thymalin's thymic T-cell restoration. The two hit host defense from separate angles (mucosal/innate barrier vs. adaptive T-cell compartment) and both temper pro-inflammatory cytokines, so they can reasonably layer for broad immune support.
Lactoferrin + Pidotimod
No known conflict in the research
Pidotimod boosts adaptive and innate defences (dendritic-cell maturation, Th1, immunoglobulins) to reduce recurrent infections, while lactoferrin provides direct antimicrobial and iron-sequestering innate defence. Coming at infection resistance from adaptive-immune priming versus direct antimicrobial action, they are complementary rather than redundant.
Lactoferrin + Thymosin Alpha-1
No known conflict in the research
Lactoferrin is an iron-sequestering defense protein with broad direct antimicrobial and immunomodulatory action, whereas Thymosin Alpha-1 restores and coordinates cellular immunity. These are distinct mechanisms (iron-based/direct microbial killing vs. T-cell/NK modulation) both supporting host defense, so they can be complementary.
Lactoferrin + Imunofan
No known conflict in the research
Lactoferrin adds broad-spectrum antimicrobial and iron-homeostasis activity plus immune/antioxidant modulation. Its mechanisms differ from imunofan's thymic pathway, so combining innate antimicrobial defense with imunofan's enhanced phagocytic and NK activity is a reasonable complementary immune-support pairing.
Lactoferrin + KPV
No known conflict in the research
Lactoferrin provides direct antimicrobial defence and iron sequestration at mucosal surfaces, while KPV suppresses the inflammatory cytokine cascade. Both are oriented toward gut/mucosal health from different mechanisms, making them a plausible complementary pair for barrier and microbiome support.
Thymalin + Elafin
No known conflict in the research
Elafin is an innate-immune protease inhibitor that protects tissue and quiets NF-kB-driven inflammation at mucosal surfaces, a distinct mechanism from Thymalin's thymic adaptive-immune restoration. Both converge on lowering NF-kB inflammatory tone through different upstream biology, so they are complementary rather than redundant.
Pidotimod + Elafin
No known conflict in the research
Pidotimod stimulates dendritic cell maturation and T-cell responses against recurrent infections, while elafin provides direct antiprotease and antimicrobial protection at epithelial surfaces. Complementary adaptive-plus-innate host defense.
Thymosin Alpha-1 + Elafin
No known conflict in the research
Elafin is an innate-defense protein that blocks destructive neutrophil proteases and has direct antimicrobial and antiviral activity, especially at mucosal surfaces. Thymosin Alpha-1 instead modulates T-cells, NK cells and cytokine tone. Different mechanisms converging on antimicrobial defense and inflammation control make them complementary rather than overlapping.
Thymosin Alpha-1 + KPV
No known conflict in the research
KPV is an alpha-MSH fragment that calms inflammation by stabilizing IκBα and blocking NF-κB, with reported antimicrobial and mucosal-repair effects. Thymosin Alpha-1 works through TLR-driven immune coordination and Th1/Th2 balancing. The two lower inflammation by different routes and could complement each other without hitting the same receptor.
Imunofan + Elafin
No known conflict in the research
Imunofan is a thymopoietin-based immunomodulator that boosts phagocytic/antimicrobial defenses and supports tissue repair, complementing elafin's antiprotease and antimicrobial actions. Different mechanisms supporting immune balance and mucosal repair.
Imunofan + KPV
No known conflict in the research
KPV is a potent NF-κB-suppressing anti-inflammatory (lowering TNF-α, IL-1β, IL-6) with mucosal/antimicrobial activity, working through a different mechanism than imunofan's thymic immunocorrection. Both push toward calmer inflammation and better mucosal defense, making them a plausible complementary anti-inflammatory pairing.
6 other pairings have no documented interaction in our data — that is not a safety clearance.
Thymalin + Alpha-MSH
Thymalin + KPV
Pidotimod + Alpha-MSH
Pidotimod + KPV
Thymosin Alpha-1 + Alpha-MSH
Imunofan + Alpha-MSH
4Related but not studied for this goal
These share some of this goal's biology and are not off-target — but their research is elsewhere: on the skin, or on another condition. Listed so you know we saw them.
Vilon shares immune (t-cell) regulation with this goal, but only 3 of its 102 research claims mention strengthen my immune system; it has not been studied for it.
Selank shares immune (t-cell) regulation with this goal, but only 3 of its 138 research claims mention strengthen my immune system; it has not been studied for it.
GHK-Cu shares immune (t-cell) regulation with this goal, but only 1 of its 151 research claims mention strengthen my immune system; it has not been studied for it.
5Compounds we looked at and left out
These share some biology with this goal, so you may have seen them recommended for it. Here is what our own research says about each.
HCG is linked to immune (t-cell) regulation, but in this compound that activity is about supporting implantation and maintaining pregnancy.
“hCG supports maternal immune cells in their function as helpers in the establishment of an adequate embryo-endometrial relationship”— from its own profile
This brief reports what published research says about these compounds. It is information, not medical advice, and not a recommendation to use anything described here. Evidence quality varies by compound and is labelled throughout. Talk to a qualified clinician before acting on any of it.
See something wrong or out of date on this page? Report it.